Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in

Status Completed

Clinical Trial Summary

There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to intravesical BCG therapy post trans-urethral resection of urinary bladder tumors for the non-invasive urinary bladder tumors.

Clinical Trial Description

The gold standard treatment for non-invasive urinary bladder tumors is by transurethral resection of bladder tumor (TURBT) and a re-TURBT when indicated, followed by adjuvant intravesical immunotherapy (BCG). However, the recurrence and progression rates of non-muscle invasive bladder cancer (NMIBC) for 5 years range from 31% to 78% and from 1% to 45%, respectively. To improve personalized care, prognostic models have been developed to help in prediction of the high-risk patients and recurrence helping in clinical and therapeutic decision-making. These models are based on standard clinic-pathological features such as T stage, grade, multifocality, sex, tumor diameter, recurrence rate, and concomitant carcinoma in situ. According to the current theories, the systemic inflammatory response triggered by cancer leads to relative neutrophilia and lymphocytopenia, creating a pro-oncogenic inflammatory condition. An elevated NLR (Neutrophil to lymphocyte ratio) implies that cell-mediated immunity is impaired and systemic inflammation is increased in inflammatory processes. Among patients with non-invasive urinary bladder tumors, an elevated NLR (Neutrophil to lymphocyte ratio) was described in the literature to be associated with advanced pathologic stage, invasiveness, and bad prognosis. The study aims to assess the role of preoperative Neutrophils to Lymphocytes ratio as a predictor for the response to BCG in patients with non-muscle invasive bladder cancer in patients following trans-urethral resection of bladder tumor (TURBT). ;

Study Design

Related Conditions & MeSH terms

BCG
Non-Muscle Invasive Bladder Urothelial Carcinoma
Urinary Bladder Cancer
Urinary Bladder Neoplasm
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT05946369
Study type	Observational
Source	Ain Shams University
Contact
Status	Completed
Phase
Start date	May 1, 2020
Completion date	May 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00872495` - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Withdrawn	`NCT05335707` - Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Completed	`NCT03998579` - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer	N/A
Not yet recruiting	`NCT04525781` - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed	`NCT02897765` - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer	Phase 1
Recruiting	`NCT05822934` - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer	Phase 3
Completed	`NCT06156787` - Patterns of Urinary Bladder Cancer in Darfur, Suda
Completed	`NCT02722538` - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer	Phase 1
Completed	`NCT02437539` - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography	Phase 1
Completed	`NCT02139371` - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography	Phase 0
Completed	`NCT03433924` - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting	`NCT03132922` - MAGE-A4ᶜ¹º³²T for Multi-Tumor	Phase 1
Recruiting	`NCT06307704` - Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients	N/A
Completed	`NCT00462488` - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ	Phase 2
Recruiting	`NCT05621837` - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting	`NCT05644041` - Intravesical Gemcitabine in Patients With NMIBC	Phase 2
Completed	`NCT04635566` - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute	N/A
Recruiting	`NCT04861584` - Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects	Phase 2
Completed	`NCT01836978` - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy	N/A
Terminated	`NCT01374789` - PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms